Nature Research Roundtable

Human Pluripotent Stem Cell Quality and Considerations

Hear what experts have to say.

About the Event

As part of our mission to advance science, STEMCELL Technologies partnered with Nature Research to host a “Nature Research Round Table” titled, “Challenges in Ensuring hPSC Quality". Global experts gathered for this event at the Springer Nature headquarters in London, UK, to tackle some of the most pertinent issues impacting the use of human pluripotent stem cells (hPSCs), ranging from fundamental biology research to therapeutic applications. The day included a series of talks followed by panel discussions on hPSC quality, including: defining quality standards for hPSCs, assessing and maintaining different states of pluripotency, and ensuring genomic integrity for use in clinical studies.

Access the Webcasts

Provided in partnership with Nature Research, keynote talks and panel discussions on "Challenges in Ensuring hPSC Quality" are available as on-demand webcasts. Access the full series below.

Event Program

Defining and Maintaining Pluripotency

Chaired by Prof. Ludovic Vallier, Wellcome Trust Sanger Institute

Pluripotency Tests
By Prof. Peter Andrews, University of Sheffield

Maintenance of hPSCs In Vitro
By Dr. Tenneille Ludwig, WiCell

hPSC Line Registration and Banking

Chaired by Dr. Joanne Mountford, University of Glasgow

Regulations Around hiPSC Registration
By Prof. Andreas Kurtz, Berlin-Brandenburg Center for Regenerative Therapies

HLA Typing Considerations for hPSC Banking
By Dr. David Turner, Scottish National Blood Transfusion Service

Standards for Pluripotent Stem Cell Banking
By Prof. Glyn Stacey, International Stem Cell Banking Initiative

Best Practices for the QC of Genome-Edited hPSC Lines

Chaired by Dr. Alex Alderton, Wellcome Trust Sanger Institute

Identifying Acquired and Background Genetic Variants in Human Pluripotent Stem Cells
By Dr. Florian Merkle, University of Cambridge

Genome Editing in Human Pluripotent Stem Cells
By Prof. Ludovic Vallier, Wellcome Trust Sanger Institute

Genomic Integrity of hPSCs: Risks and Pitfalls

Chaired by Prof. Peter Andrews, University of Sheffield

The Process of hPSC Adaptation
By Dr. Ivana Barbaric, University of Sheffield

Genomic Integrity of hPSCs
By Prof. Martin Pera, The Jackson Laboratory

hPSC Lines for Cell Therapies

Chaired by Prof. Christine Mummery, Leiden University Medical Center

Retinal Cell Therapy Using hES Cells
By Prof. Peter Coffey, University College London

Parkinson's Disease Therapy with hESC Cells
By Prof. Malin Parmar, Lund University

hPSC Lines as Disease Models
By Prof. Christine Mummery, LUMC, Leiden University

Meet the Speakers

The University of Sheffield

Peter Andrews is currently co-director of the Centre for Stem Cell Biology at the University of Sheffield. His research focuses on the biology of hPSCs, and particularly their mechanisms of fate determination, as well as their susceptibility to genetic change upon long-term culture. He previously directed the Pluripotent Stem Cell Platform and coordinated the International Stem Cell Initiative, which has worked to characterize standard markers and culture conditions for human ES cells and is currently seeking to establish a study group to collate and monitor data on the origins and potential consequences of acquired genetic variants of hPSC.

See more >

Professor and Chair of Developmental Biology
Leiden University Medical Centre

Christine Mummery pioneered studies on cardiomyocytes from human embryonic stem cells, was among the first to inject them in mouse hearts after myocardial infarction and currently develops cardiovascular disease models based on human induced pluripotent stem cells. In 2007, she was a joint Harvard Stem Cell Institute/Radcliffe fellow. She is presently on the board and vice president of ISSCR and a member of the Royal Netherlands Academy of Science.

See more >

Lund University

Malin Parmar is a Professor at Lund University, Sweden, where she focuses on bringing new cell-based therapies to the clinic to treat Parkinson’s disease by investigating cell fate specification in the developing brain and applying the findings to stem cells. Her group also develops technologies for direct neural conversion to generate midbrain dopamine neurons, and their current focus is to learn how to direct and efficiently drive controlled differentiation of human stem cells into subtype-specific neurons.

See more >

University College London and University of California

Peter Coffey founded the London Project to Cure Blindness in 2007 to bring stem cell therapy for retinal diseases to the clinic. His work using iPSC-derived RPE cells to halt visual deterioration from age-related eye diseases recently resulted in the first clinical stem cell trials to attempt to treat blindness. Peter Coffey is also currently a professor at UCSB's Neuroscience Research Institute and co-director of the campus's Center for Stem Cell Biology & Engineering.

See more >